News
MTEM
1.470
-1.01%
-0.015
Weekly Report: what happened at MTEM last week (0408-0412)?
Weekly Report · 4d ago
Molecular Templates to Cut 30% of Staff, Chief Medical Officer
Biopharmaceutical company Molecular Templates says it will lay off about 30% of its workforce. The cuts are expected to be complete by the end of April. The company says the cuts will allow it to continue clinical studies on three potential candidates. The Austin, Texas-based company will also cut its chief medical officer.
Dow Jones · 6d ago
Molecular Templates Inc Announces Layoffs, CMO Resignation
TipRanks · 04/12 20:32
Molecular Templates Inc Estimates That It Will Incur Aggregate Pre-Tax Charges Of ~$0.1M In Connection With Reduction In Force; Effective April 30; Reduction To Extend Resources To Allow Co To Continue To Support Clinical Studies For MT-6402, MT-8421 And MT-0169
Benzinga · 04/12 20:26
Molecular Templates Inc Says Reduction In Force Would Reduce Company's Current Workforce By ~30%; Approved A Reduction In Force; Expects That Reduction In Force Will Be Complete By End Of April 2024
Benzinga · 04/12 20:25
MOLECULAR TEMPLATES INC - APPROVED A REDUCTION IN FORCE
Reuters · 04/12 20:23
MOLECULAR TEMPLATES: REDUCTION TO EXTEND RESOURCES TO ALLOW CO TO CONTINUE TO SUPPORT CLINICAL STUDIES FOR MT-6402, MT-8421 AND MT-0169
Reuters · 04/12 20:23
MTEM Stock Earnings: Molecular Templates Beats EPS, Misses Revenue for Q4 2023
Molecular Templates reported earnings per share of -73 cents for the fourth quarter of 2023. The company reported revenue of $7.02 million. This was 9.70% worse than the analyst estimate for revenue. Molecular Templates also reported results for the third quarter of 2018.
Investorplace · 04/11 17:52
12 Health Care Stocks Moving In Tuesday's After-Market Session
Jaguar Health (NASDAQ:JAGX) shares rose 25.3% to $0.11 during Tuesday's after-market session. The company's market cap stands at $31.1 million. ATyr Pharma shares rose 10.45% and Corvus Pharma shares increased by 7.36%. Apyx Medical shares declined by 6.1% during the session.
Benzinga · 04/09 20:31
What's Going On With Molecular Templates Stock?
Molecular Templates, Inc (NASDAQ:MTEM) shares are moving on heavy trading volume Tuesday. The company presented interim data from MT-6402 Phase I study in patients with PD-L1+ solid tumors. Molecular Templates does not pay a dividend.
Benzinga · 04/09 16:37
Molecular Templates, Acorda Therapeutics, MyMD Pharmaceuticals among healthcare movers
Molecular Templates, Acorda Therapeutics, MyMD Pharmaceuticals among healthcare movers. S&P 500 Health Care Sector +0.11% to 1666.38. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index.
Seeking Alpha · 04/09 14:00
Molecular Templates Presents Interim Data From MT-6402 Phase I Study In Patients With PD-L1+ Solid Tumors At 2024 AACR Annual Meeting
MT-6402 has been well tolerated with no drug-related Grade 4 or 5 adverse events, the company says. An early monotherapy efficacy signal in head and neck squamous cell carcinoma was identified. Two patients in the study showed partial responses to the drug. The drug acts uniquely from other checkpoint agents.
Benzinga · 04/09 12:27
Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer
Molecular Templates, Inc. Will present a poster at the 2024 American Association for Cancer Research Annual Meeting in San Diego. The company is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted cancer therapies. MTEM has announced monotherapy response activity in Head and Neck Cancer.
Barchart · 04/09 07:11
Weekly Report: what happened at MTEM last week (0401-0405)?
Weekly Report · 04/08 11:02
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Protara Therapeutics (NASDAQ:TARA) stock increased by 40.3% to $5.64 during Friday's pre-market session. Candel Therapeutic shares moved upwards by 25.93% during the session. The company's market cap stands at $236.5 million.
Benzinga · 04/05 12:09
Weekly Report: what happened at MTEM last week (0325-0329)?
Weekly Report · 04/01 11:01
Molecular Templates Inc reports results for the quarter ended in December - Earnings Summary
Molecular Templates Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 73 cents per share. Revenue rose 168.7% to $7.02 million from the same quarter last year. The average analyst rating on the shares is "buy"
Reuters · 03/29 13:10
Molecular Templates GAAP EPS of -$0.73, revenue of $7.02M
Seeking Alpha · 03/29 12:35
*Molecular Templates 4Q Research and Development Expenses $8.8M >MTEM
Dow Jones · 03/29 12:22
*Molecular Templates 4Q Rev $7.02M >MTEM
Dow Jones · 03/29 12:21
More
Webull provides a variety of real-time MTEM stock news. You can receive the latest news about Molecular Templates Inc through multiple platforms. This information may help you make smarter investment decisions.
About MTEM
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. The Company’s proprietary drug platform technology, known as engineered toxin bodies (ETBs), leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer. Its product pipeline includes MT-6402, MT-8421 and MT-0169. MT-6402 is an ETB consisting of a single chain variable fragments (scFv), with affinity for PD-L1, fused to the enzymatically active de-immunized SLTA and a HLA-A*02 class I antigen derived from the human cytomegalovirus (HCMV) pp65 protein. MT-8421, its ETB targeting CTLA-4, along with MT-6402. MT-0169 is designed to destroy CD38+ tumour cells through internalization of CD38 and cell destruction via a novel mechanism of action (enzymatic ribosomal destruction and immunogenic cell death).